Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42


Preclinical modeling highlights the therapeutic potential of hematopoietic stem cell gene editing for correction of SCID-X1.

Schiroli G, Ferrari S, Conway A, Jacob A, Capo V, Albano L, Plati T, Castiello MC, Sanvito F, Gennery AR, Bovolenta C, Palchaudhuri R, Scadden DT, Holmes MC, Villa A, Sitia G, Lombardo A, Genovese P, Naldini L.

Sci Transl Med. 2017 Oct 11;9(411). pii: eaan0820. doi: 10.1126/scitranslmed.aan0820.


Vectofusin-1 Promotes RD114-TR-Pseudotyped Lentiviral Vector Transduction of Human HSPCs and T Lymphocytes.

Piovan C, Marin V, Scavullo C, Corna S, Giuliani E, Bossi S, Galy A, Fenard D, Bordignon C, Rizzardi GP, Bovolenta C.

Mol Ther Methods Clin Dev. 2017 Mar 8;5:22-30. doi: 10.1016/j.omtm.2017.02.003. eCollection 2017 Jun 16.


Codon Optimization Leads to Functional Impairment of RD114-TR Envelope Glycoprotein.

Zucchelli E, Pema M, Stornaiuolo A, Piovan C, Scavullo C, Giuliani E, Bossi S, Corna S, Asperti C, Bordignon C, Rizzardi GP, Bovolenta C.

Mol Ther Methods Clin Dev. 2017 Jan 11;4:102-114. doi: 10.1016/j.omtm.2017.01.002. eCollection 2017 Mar 17.


Lentiviral Vector Gene Therapy Protects XCGD Mice From Acute Staphylococcus aureus Pneumonia and Inflammatory Response.

Farinelli G, Jofra Hernandez R, Rossi A, Ranucci S, Sanvito F, Migliavacca M, Brombin C, Pramov A, Di Serio C, Bovolenta C, Gentner B, Bragonzi A, Aiuti A.

Mol Ther. 2016 Oct;24(10):1873-1880. doi: 10.1038/mt.2016.150. Epub 2016 Jul 26.


RD-MolPack technology for the constitutive production of self-inactivating lentiviral vectors pseudotyped with the nontoxic RD114-TR envelope.

Marin V, Stornaiuolo A, Piovan C, Corna S, Bossi S, Pema M, Giuliani E, Scavullo C, Zucchelli E, Bordignon C, Rizzardi GP, Bovolenta C.

Mol Ther Methods Clin Dev. 2016 May 11;3:16033. doi: 10.1038/mtm.2016.33. eCollection 2016.


Production of lentiviral vectors.

Merten OW, Hebben M, Bovolenta C.

Mol Ther Methods Clin Dev. 2016 Apr 13;3:16017. doi: 10.1038/mtm.2016.17. eCollection 2016. Review.


Mutational analysis of the HIV-1 auxiliary protein Vif identifies independent domains important for the physical and functional interaction with HIV-1 reverse transcriptase.

Kataropoulou A, Bovolenta C, Belfiore A, Trabatti S, Garbelli A, Porcellini S, Lupo R, Maga G.

Nucleic Acids Res. 2014 Apr;42(6):4144. doi: 10.1093/nar/gku195. Epub 2014 Mar 13. No abstract available.


RD2-MolPack-Chim3, a packaging cell line for stable production of lentiviral vectors for anti-HIV gene therapy.

Stornaiuolo A, Piovani BM, Bossi S, Zucchelli E, Corna S, Salvatori F, Mavilio F, Bordignon C, Rizzardi GP, Bovolenta C.

Hum Gene Ther Methods. 2013 Aug;24(4):228-40. doi: 10.1089/hgtb.2012.190. Epub 2013 Aug 3.


Therapeutic genes for anti-HIV/AIDS gene therapy.

Bovolenta C, Porcellini S, Alberici L.

Curr Pharm Biotechnol. 2013;14(5):488-500. Review.


Chim3 confers survival advantage to CD4+ T cells upon HIV-1 infection by preventing HIV-1 DNA integration and HIV-1-induced G2 cell-cycle delay.

Porcellini S, Gubinelli F, Alberici L, Piovani BM, Rizzardi GP, Bovolenta C.

Blood. 2010 May 20;115(20):4021-9. doi: 10.1182/blood-2009-09-243030. Epub 2010 Mar 10.


Mutational analysis of the HIV-1 auxiliary protein Vif identifies independent domains important for the physical and functional interaction with HIV-1 reverse transcriptase.

Kataropoulou A, Bovolenta C, Belfiore A, Trabatti S, Garbelli A, Porcellini S, Lupo R, Maga G.

Nucleic Acids Res. 2009 Jun;37(11):3660-9. doi: 10.1093/nar/gkp226. Epub 2009 Apr 15.


Transcriptional enhancers induce insertional gene deregulation independently from the vector type and design.

Maruggi G, Porcellini S, Facchini G, Perna SK, Cattoglio C, Sartori D, Ambrosi A, Schambach A, Baum C, Bonini C, Bovolenta C, Mavilio F, Recchia A.

Mol Ther. 2009 May;17(5):851-6. doi: 10.1038/mt.2009.51. Epub 2009 Mar 17.


The F12-Vif derivative Chim3 inhibits HIV-1 replication in CD4+ T lymphocytes and CD34+-derived macrophages by blocking HIV-1 DNA integration.

Porcellini S, Alberici L, Gubinelli F, Lupo R, Olgiati C, Rizzardi GP, Bovolenta C.

Blood. 2009 Apr 9;113(15):3443-52. doi: 10.1182/blood-2008-06-158790. Epub 2009 Feb 11.


Naturally occurring C-terminally truncated STAT5 is a negative regulator of HIV-1 expression.

Crotti A, Lusic M, Lupo R, Lievens PM, Liboi E, Della Chiara G, Tinelli M, Lazzarin A, Patterson BK, Giacca M, Bovolenta C, Poli G.

Blood. 2007 Jun 15;109(12):5380-9. Epub 2007 Mar 1.


Heterogeneity of signal transducer and activator of transcription binding sites in the long-terminal repeats of distinct HIV-1 subtypes.

Crotti A, Chiara GD, Ghezzi S, Lupo R, Jeeninga RE, Liboi E, Lievens PM, Vicenzi E, Bovolenta C, Berkhout B, Poli G.

Open Virol J. 2007;1:26-32. doi: 10.2174/1874357900701010026. Epub 2007 Oct 20.


Double doors and gatekeepers: HIV co-receptors and chemokines.

Bovolenta C, Biswas P, Vicenzi E, Poli G.

Drug News Perspect. 1998 Dec;11(10):620-4.


Blocking HIV-1 Vif restores a natural mechanism of intracellular antiviral defense.

Bovolenta C.

Curr Drug Targets Immune Endocr Metabol Disord. 2004 Dec;4(4):257-63. Review.


IFN-gamma and IL-12 differentially regulate CC-chemokine secretion and CCR5 expression in human T lymphocytes.

Losana G, Bovolenta C, Rigamonti L, Borghi I, Altare F, Jouanguy E, Forni G, Casanova JL, Sherry B, Mengozzi M, Trinchieri G, Poli G, Gerosa F, Novelli F.

J Leukoc Biol. 2002 Oct;72(4):735-42.


Retroviral interference on STAT activation in individuals coinfected with human T cell leukemia virus type 2 and HIV-1.

Bovolenta C, Pilotti E, Mauri M, Panzeri B, Sassi M, Dall'Aglio P, Bertazzoni U, Poli G, Casoli C.

J Immunol. 2002 Oct 15;169(8):4443-9.


Expression and activation of a C-terminal truncated isoform of STAT5 (STAT5 Delta) following interleukin 2 administration or AZT monotherapy in HIV-infected individuals.

Bovolenta C, Camorali L, Mauri M, Ghezzi S, Nozza S, Tambussi G, Lazzarin A, Poli G.

Clin Immunol. 2001 Apr;99(1):75-81.


The binding subunit of pertussis toxin inhibits HIV replication in human macrophages and virus expression in chronically infected promonocytic U1 cells.

Alfano M, Vallanti G, Biswas P, Bovolenta C, Vicenzi E, Mantelli B, Pushkarsky T, Rappuoli R, Lazzarin A, Bukrinsky M, Poli G.

J Immunol. 2001 Feb 1;166(3):1863-70.


Immunologic reconstitution by interleukin-2: facts and open questions.

Vallanti G, Bovolenta C, Brambilla A, Tambussi G, Lazzarin A, Vicenzi E, Poli G.

J Biol Regul Homeost Agents. 2000 Jan-Mar;14(1):41-4. Review.


Constitutive activation of STATs upon in vivo human immunodeficiency virus infection.

Bovolenta C, Camorali L, Lorini AL, Ghezzi S, Vicenzi E, Lazzarin A, Poli G.

Blood. 1999 Dec 15;94(12):4202-9.


Interleukin-10 (IL-10) selectively enhances CIS3/SOCS3 mRNA expression in human neutrophils: evidence for an IL-10-induced pathway that is independent of STAT protein activation.

Cassatella MA, Gasperini S, Bovolenta C, Calzetti F, Vollebregt M, Scapini P, Marchi M, Suzuki R, Suzuki A, Yoshimura A.

Blood. 1999 Oct 15;94(8):2880-9.


Defective nef alleles in a cohort of hemophiliacs with progressing and nonprogressing HIV-1 infection.

Brambilla A, Turchetto L, Gatti A, Bovolenta C, Veglia F, Santagostino E, Gringeri A, Clementi M, Poli G, Bagnarelli P, Vicenzi E.

Virology. 1999 Jul 5;259(2):349-68.


HIV infection and signal transduction.

Bovolenta C, Camorali L, Lorini AL, Poli G.

J Biol Regul Homeost Agents. 1998 Jul-Sep;12(3):63-6. Review. No abstract available.


Positive selection of apoptosis-resistant cells correlates with activation of dominant-negative STAT5.

Bovolenta C, Testolin L, Benussi L, Lievens PM, Liboi E.

J Biol Chem. 1998 Aug 14;273(33):20779-84.


Selective association of a 22-38 kDa glycoprotein with MHC class II DP antigen on activated human lymphocytes at the plasma membrane.

Carra G, Giunta M, Benati C, Bovolenta C, Tridente G, Libonati M, Gerosa F.

Mol Immunol. 1996 Feb;33(3):269-78.


Vesicular stomatitis virus infection induces a nuclear DNA-binding factor specific for the interferon-stimulated response element.

Bovolenta C, Lou J, Kanno Y, Park BK, Thornton AM, Coligan JE, Schubert M, Ozato K.

J Virol. 1995 Jul;69(7):4173-81.


Molecular interactions between interferon consensus sequence binding protein and members of the interferon regulatory factor family.

Bovolenta C, Driggers PH, Marks MS, Medin JA, Politis AD, Vogel SN, Levy DE, Sakaguchi K, Appella E, Coligan JE, et al.

Proc Natl Acad Sci U S A. 1994 May 24;91(11):5046-50.


Multiple cis-acting elements are required for proper transcription of the mouse V delta 1 T cell receptor promoter.

Punturieri A, Shirakata Y, Bovolenta C, Kikuchi G, Coligan JE.

J Immunol. 1993 Jan 1;150(1):139-50.


c-fos proto-oncogene transient transcription is negatively affected in the ELa4-2 transformed rat cell line.

Tognon M, Romanelli MG, Cattozzo EM, Bovolenta C, Liboi E.

Pathobiology. 1993;61(5-6):288-92.


Mediastinal large-cell lymphoma with sclerosis. Genotypic analysis establishes its B nature.

Scarpa A, Bonetti F, Menestrina F, Menegazzi M, Chilosi M, Lestani M, Bovolenta C, Zamboni G, Fiore-Donati L.

Virchows Arch A Pathol Anat Histopathol. 1987;412(1):17-21.


Supplemental Content

Loading ...
Support Center